Shares of Anika Therapeutics Inc (NASDAQ:ANIK) have received a consensus broker rating score of 2.00 (Buy) from the two analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation and one has issued a strong buy recommendation on the company. Anika Therapeutics’ rating score has declined by 100% from 90 days ago as a result of a number of analysts’ ratings changes.
Brokers have set a 12-month consensus price objective of $68.00 for the company and are forecasting that the company will post $0.25 EPS for the current quarter, according to Zacks. Zacks has also given Anika Therapeutics an industry rank of 195 out of 265 based on the ratings given to its competitors.
A number of brokerages have recently commented on ANIK. Barrington Research lowered shares of Anika Therapeutics from an “outperform” rating to a “market perform” rating in a report on Friday, February 23rd. BidaskClub lowered shares of Anika Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 24th. Sidoti began coverage on shares of Anika Therapeutics in a report on Friday, January 26th. They issued a “buy” rating on the stock. Zacks Investment Research lowered shares of Anika Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, February 26th. Finally, First Analysis raised shares of Anika Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $45.00 to $68.00 in a report on Wednesday, January 24th.
Anika Therapeutics (NASDAQ:ANIK) traded up $0.06 during trading on Monday, reaching $53.49. 67,098 shares of the company were exchanged, compared to its average volume of 110,102. The company has a market cap of $785.14, a price-to-earnings ratio of 27.29, a PEG ratio of 3.40 and a beta of 1.78. Anika Therapeutics has a twelve month low of $41.64 and a twelve month high of $69.81.
Anika Therapeutics (NASDAQ:ANIK) last issued its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $0.38 EPS for the quarter, missing the Zacks’ consensus estimate of $0.41 by ($0.03). The company had revenue of $29.39 million during the quarter, compared to the consensus estimate of $29.85 million. Anika Therapeutics had a return on equity of 11.91% and a net margin of 28.05%. Anika Therapeutics’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.54 EPS. analysts forecast that Anika Therapeutics will post 1.57 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Anika Therapeutics Inc (ANIK) Given Average Rating of “Buy” by Analysts” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/3254228/anika-therapeutics-inc-anik-given-average-rating-of-buy-by-analysts.html.
About Anika Therapeutics
Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.